Latest Trials Latest NewsFAQ

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

MRI Iron Oxide Imaging for Lymph Node Staging in Esophageal Cancer

Phase 1

Withdrawn

Conditions: Esophageal Cancer

Interventions: Drug: Ferumoxytol
Device: MRI 3T scanner

First Posted Date: 2016-02-24

Last Posted Date: 2016-05-13

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT02689401

Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia

Phase 2

Completed

Conditions: Waldenstrom Macroglobulinemia

Interventions: Drug: ABT199

First Posted Date: 2016-02-09

Last Posted Date: 2022-05-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 33

Registration Number: NCT02677324

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States

and more 1 locations

Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome

Not Applicable

Active, not recruiting

Conditions: Recurrent, Refractory, or High Risk Leukemias
Matched Targeted Therapy

Interventions: Genetic: Leukemia Profiling

First Posted Date: 2016-02-01

Last Posted Date: 2024-11-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 338

Registration Number: NCT02670525

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

and more 12 locations

Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

Conditions: Multiple Myeloma in Relapse
Multiple Myeloma

First Posted Date: 2016-01-28

Last Posted Date: 2017-08-28

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT02666209

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer

Phase 1

Terminated

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Carcinoma

Interventions: Drug: Paclitaxel
Drug: Ricolinostat
Drug: Bevacizumab

First Posted Date: 2016-01-25

Last Posted Date: 2019-11-08

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 6

Registration Number: NCT02661815

Locations: 🇺🇸
Massacusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

GO-203-2C + Bortezomib For Relapsed Or Refractory MM

Phase 1

Withdrawn

Conditions: Multiple Myeloma
Multiple Myeloma in Relapse
Refractory Multiple Myeloma

Interventions: Drug: GO-203-2C
Drug: Bortezomib

First Posted Date: 2016-01-18

Last Posted Date: 2017-07-05

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT02658396

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer

Phase 2

Active, not recruiting

Conditions: Thyroid Cancer

Interventions: Drug: Regorafenib

First Posted Date: 2016-01-18

Last Posted Date: 2024-11-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 8

Registration Number: NCT02657551

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors

Phase 2

Withdrawn

Conditions: Solid Tumor

Interventions: Drug: BAY 1000394

First Posted Date: 2016-01-15

Last Posted Date: 2016-07-01

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT02656849

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Ribociclib
Drug: T-DM1
Drug: Trastuzumab
Drug: Fulvestrant

First Posted Date: 2016-01-15

Last Posted Date: 2022-08-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 25

Registration Number: NCT02657343

Locations: 🇺🇸
Massacusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer Radiation

Interventions: Device: Prosigna

First Posted Date: 2016-01-12

Last Posted Date: 2024-04-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 671

Registration Number: NCT02653755

Locations: 🇺🇸
Lifespan Cancer Institute, Providence, Rhode Island, United States
🇺🇸
NYU Langone Health, New York, New York, United States
🇺🇸
Memorial Sloane Kettering Cancer Center, New York, New York, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy